Eleftheria A. Anastasopoulou

Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence

Elizabeth A. Mittendorf, Alexandros Ardavanis, James T. Symanowski et al. · Annals of Oncology · 2016 · 107 citations · Full text

Vaccination, Breast Oncology, Breast Cancer Patients +10

Differential intratumoral distributions of CD8 and CD163 immune cells as prognostic biomarkers in breast cancer

Sotirios P. Fortis, Michael Sofopoulos, Nectaria N. Sotiriadou et al. · Journal for ImmunoTherapy of Cancer · 2017 · 93 citations · Full text

Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence

Tommy A. Brown, Elizabeth A. Mittendorf, Diane F. Hale et al. · Breast Cancer Research and Treatment · 2020 · 75 citations · Full text

AE37 peptide vaccination in prostate cancer: a 4-year immunological assessment updates on a phase I trial

Sonia A. Perez, Eleftheria A. Anastasopoulou, Panagiotis Tzonis et al. · Cancer Immunology Immunotherapy · 2013 · 32 citations · Full text

Vaccination, Ae37 Peptide Vaccination, Immunology +8

AE37 peptide vaccination in prostate cancer: identification of biomarkers in the context of prognosis and prediction

Sonia A. Perez, Eleftheria A. Anastasopoulou, Michael Papamichail et al. · Cancer Immunology Immunotherapy · 2014 · 20 citations · Full text

Biomarker (Medicine), Prognostic Biomarkers, Urology +8